The Journal of Medical Sciences

Register      Login

VOLUME 4 , ISSUE 4 ( October-December, 2018 ) > List of Articles

ORIGINAL ARTICLE

Immunohistochemical Study of CK 5/6 in Benign and Malignant Breast Lesions

Ankita Das, Rashmi MV

Keywords : Benign breast disease, Breast carcinoma, CK 5/6

Citation Information : Das A, MV R. Immunohistochemical Study of CK 5/6 in Benign and Malignant Breast Lesions. J Med Sci 2018; 4 (4):95-102.

DOI: 10.5005/jp-journals-10045-0096

License: CC BY-NC 4.0

Published Online: 01-12-2018

Copyright Statement:  Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Introduction: Breast lesions are very common diseases worldwide. Benign breast disease (BBD) accounting for most breast problem in females. Carcinoma breast is one of the most common human neoplasms rapidly replacing cancer of cervix as the most important leading site of cancer in most urban populations of India. A panel of antibodies, improved antigen retrieval techniques have all contributed to the use of immunohistochemistry (IHC) in solving diagnostic problems in breast pathology. Materials and methods: This is a cross-sectional study done in a hospital in Tumkur, Karnataka for 1.5 years. Total of 41 benign and 41 malignant biopsies of breast neoplasm from female patients was studied. All breast masses were analyzed systematically by clinical history, physical examination, histopathological examination along with the immunohistochemical study of CK 5/6. All collected data were entered into a master sheet and fed into computer software for statistical analysis using Pearson\'s Chi-square test. Results: In our study patients belonged to the age group of 15 –70 years. Benign lesions were common in the age group of 21–30 years, and malignant lesions were common in the age group of 51–60 years. The most frequent benign neoplasm was a fibroadenoma (74%) and in malignancy, infiltrating ductal carcinoma-NOS (85%). Most of the malignant cases were of size T2 (76%) and grade II (66%) and without any lymph node metastatic deposits (83%). All benign breast lesions showed positive expression for CK 5/6; the staining index of benign lesions varied from 5–9. Fibroadenomas showed stain index range of 6–8. Highest stain index of 9 was seen in fibrocystic with ductal epithelial hyperplasia. In malignant lesions, all cases were negative for CK 5/6 expression except 3 IDC-NOS cases which were grade III (poorly-differentiated) and showed weak CK 5/6 expression with stain index of 2.There was a statistically significant association between CK 5/6 stain index with grading and lymph node metastasis. Conclusion: Immunohistochemistry (IHC) is an integral part of the pathology. Although hematoxylin and eosin (H&E) stain remain the gold standard method for diagnosis, IHC provides useful vital information in grey zone cases. CK 5/6, as a component of panels along with AE1/AE3 and myoepithelial markers, help to differentiate benign and malignant breast lesions in cases of interobserver variability. Grade III breast carcinoma cases, if positive for CK 5/6, imply a ‘basal-like’ molecular phenotype and signify a poor prognosis. These tumors require aggressive intervention. CK 5/6 can help provide prognostic information and better treatment modalities.


PDF Share
  1. Hatim K, Laxmikant N, Mulla T. Patterns and prevalence of benign breast disease in western India. Int J Res Med Sci 2017; 5(2):684-688.
  2. Sangma M, Panda K, Dasiah S. A clinico-pathological study on benign breast diseases. J Clin Diagn Res 2013;7(3):503-506.
  3. Nandakumar A, Ramnath T, Chaturvedi M. The magnitude of cancer breast in India: A summary. Indian J Surg Oncol 2010;1:8-9.
  4. Saranath D, Khanna A. Current status of cancer burden: Global and Indian scenario. Biomed Res J 2014; 1(1):1-5.
  5. Babu GR, Lakshmi SB, Thiyagarajan AT. Epidemiological correlates of breast cancer in south India. Asian Pac J Cancer Prev 2013;14(9):5077-5083.
  6. Yeh IT, Mies C. Application of immunohistochemistry to breast lesions. Arch Pathol Lab Med 2008;132:349-358.
  7. Bhalla A, Manjari M, Kahlon K, Kumar P, Kalra N. Cytokeratin 5/6 expression in benign and malignant breast lesions. Indian J Pathol Microbiol 2010; 53:676-680.
  8. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, et al. Germline BRCA 1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95:1482-1485.
  9. Kapoor S, Kumar A, Singh A, Singh H, Singla R. Varied pattern of breast diseases-A study of 443 Cases. IOSR J Dental and Medical Sci 2016;15(3):36-49.
  10. Mudholkar GV, Mashal NS, Kawade BS. Histopathological study of neoplastic lesions of breast. Ind Med Gazette 2012; 45:118-122.
  11. Ginsburg OM, Martin LJ, Boyd NF. Mammographic density, lobular involution, and risk of breast cancer. Br J Cancer 2008; 99:1369-1374.
  12. Akhtar K, Bharduaj S, Naim M, Mansoor T, Sherwani R. Factors predicting the axillary lymph node metastasis in breast cancer: Is axillary node clearance indicated in every breast cancer patient? Ind J Surg 2011;73(5):331-335.
  13. Carter C, Allen C, Henson D. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187.
  14. Ahmad Z, Khurshid A, Qureshi A, Idress R, Asghar N, Kayani N. Breast carcinoma grading, estimation of tumor size, axillary lymph node status, staging, and Nottingham Prognostic Index scoring on mastectomy specimens. Ind J Pathol Microbiol 2009;52(4):477-481.
  15. Akhtar K, Bharduaj S, Naim M, Mansoor T, Sherwani R. Diagnostic value of Cytokeratin 5 and Cytokeratin 6 in benign and malignant lesions of breast. Annuals of Pathology and Laboratory Med 2015;2(4):45-49.
  16. Otterbach F, Bunkfalvi A, Bergner S, Decker T, Krech R, Boecker W. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathol 2000;37:232-240.
  17. Yanping D, Qiurong R. The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast. J Huazhong Univ Med Sci 2006;26(4):405-407.
  18. Lacroix-Triki M, Mery E, Voigt J. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast: A comparative study with 34âE12 antibody. Virchows Arch 2003; 442(6):548-554.
  19. Herranz M. The expression of cytokeratin5/6 in Invasive Ductal Carcinoma of breast: Association with other clinical and biological parameters. Sci Stud Onc 2014;1:8-9.
  20. Rehim D, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson J. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-671.
  21. Dent R, Trudeau M, Pritchard KI, Hanna WM. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13(15):4429- 4434.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.